Purpose of this Study
What happens during the study?
- You'll get the study medicine through an IV every 3 weeks
- Doctors will take blood and urine samples
- You'll have regular CT or MRI scans to check your health
Who Can Participate?
Eligibility
Who can join this study?
- Adults who are 18 or older
- Have a type of cancer that has spread and shows a special change called MET amplification
- Have already tried at least one treatment for their cancer
- Don’t have any other good treatment options that are likely to help them live longer
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
Why is this study happening?
Doctors are testing a new medicine called Telizotuzumab Adjzutecan (ABBV-400) to see if it is safe and works well for people with certain types of cancer that have spread and have a special change in their cells called MET amplification.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification [M25-279]
Principal Investigator
John
Strickler
Protocol Number
PRO00118702
NCT ID
NCT07196644
Phase
II
Enrollment Status
Pending Open to Enrollment